Andrew Wagner
Dana-Farber Cancer Institute
Boston
Massachusetts
Name/email consistency: high
- Tivantinib (ARQ 197), a selective inhibitor of MET, in patients with microphthalmia transcription factor-associated tumors: Results of a multicenter phase 2 trial. Wagner, A.J., Goldberg, J.M., Dubois, S.G., Choy, E., Rosen, L., Pappo, A., Geller, J., Judson, I., Hogg, D., Senzer, N., Davis, I.J., Chai, F., Waghorne, C., Schwartz, B., Demetri, G.D. Cancer (2012)
- Treatment of advanced soft tissue sarcoma: conventional agents and promising new drugs. Wagner, A. J. Natl. Compr. Canc. Netw (2007)









